Participants 37 127 5
planned coronary stent implantation in patients with chronic kidney disease (ESPRIT Trial)
Participants 191 229 5
in patients with mild renal impairment
Participants 386 450 6
patients who underwent percutaneous coronary intervention (PCI).
Participants 454 613 6
analyzed 48-hour and 30-day outcomes of patients enrolled in the Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) trial.
Participants 614 771 4
Patients were randomly assigned to placebo or eptifibatide as an adjunct to stent implantation (1,755 with CrCl > or =60 ml/min and 289 with CrCl <60 ml/min)
Participants 924 1097 3
Patients with CrCl <60 ml/min were more likely to be older, women, hypertensive, and have a history of coronary artery bypass surgery, stroke, or peripheral vascular disease
Participants 1642 1680 3
in patients with mild renal impairment
